Page 1

Exhibit 99.1 Eton Pharmaceuticals Reports Second Quarter Financial Results DEER PARK , Ill . , Aug 16 , 2021 ( GLOBE NEWSWIRE ) - ) — Eton Pharmaceuticals , Inc ( Nasdaq : ETON ) , an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases , today reported financial results for the second quarter ended June 30 , 2021 . " During the second quarter we received FDA - approval for Rezipres® , which is now the fourth FDA - approved product in our portfolio , " said Sean Brynjelsen CEO of Eton Pharmaceuticals . " We look forward to launching Rezipres® in the coming months . We also expanded our pediatric endocrinology portfolio with the acquisition of U.S. and Canadian rights to the ZENEO® Hydrocortisone autoinjector . ZENEO Hydrocortisone is a terrific strategic fit with ALKINDI SPRINKLE , and we look forward to working with Crossject to bring it to market as quickly as possible . " Second Quarter Business Highlights Received U.S. Food and Drug Administration ( FDA ) approval of Rezipres® , a ready - to - use formulation of ephedrine injection . Eton expects the product to be commercially available in the coming months . Acquired U.S. and Canadian rights to ZENEO® Hydrocortisone autoinjector . The product candidate is expected to be the first needle - free autoinjector for the treatment of adrenal crisis . Eton expects the product to be submitted to the FDA in 2023 . Progressed ALKINDI SPRINKLE commercial launch . ALKINDI SPRINKE launch activities expanded in the quarter as the company was able to shift from virtual meetings to in - person meetings with physicians and industry leaders . The product continues to receive a favorable reception from physicians , patients , and payers . Commercial Update The second quarter of 2021 was ALKINDI SPRINKLE's second full quarter of commercial launch . Eton continues to see increasing adoption of the product , and the number of patients on treatment has grown month over month . As a result of fewer COVID - 19 restrictions during the quarter , the ALKINDI SPRINKLE sales force was able to prioritize in - person meetings for the first time since the product's launch . In - person meetings are now the primary method of engagement , surpassing telephone and video calls in the quarter . As a result of favorable feedback from the in - person meetings , Eton expects to expand its sales force to drive more frequent engagement with physicians and potentially faster patient conversion . ALKINDI SPRINKLE has received favorable support from payers that recognize the importance of precision dosing in the treatment of adrenal insufficiency . The company has seen a very high rate of new patients converting from initial quick starts to commercial reimbursement . Currently more than 90 % of patients on treatment are being reimbursed . During the quarter Eton expanded its active engagement with the adrenal insufficiency community . The company sponsored continuing medical education programs for healthcare professionals to raise awareness of the significant risks and lifelong side effects associated with over or under - dosing when treating adrenal insufficiency in pediatric patients . Eton continues to work with key advocacy partners to help raise awareness of adrenal insufficiency and is hosting an advisory panel with key opinion leaders in the adrenal insufficiency community in late August .